![Box of Farxiga](https://insightlinks.storage.googleapis.com/cardiacwire/2023/05/Farxiga-FDA-5.11.2023-scaled-e1683761580241.jpg)
Cardiology Pharmaceuticals May 11, 2023
AstraZeneca’s Farxiga Lands Heart Failure FDA Extension May 11, 2023
AstraZeneca’s Farxiga (dapagliflozin) oral SGLT2 inhibitor just landed FDA approval for a far wider range of heart failure patients, now covering risk reduction among all adults with HF -- regardless of their left ventricular ejection fraction status.
![tirzepatide injection](https://insightlinks.storage.googleapis.com/cardiacwire/2023/05/tirzepatide-5.8.2023-scaled-e1683241658726.jpg)
Cardiology Pharmaceuticals May 8, 2023
Tirzepatide Delivers in SURMOUNT-2 May 8, 2023
Results from Eli Lilly’s SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide drives meaningful weight loss among obese or overweight adults with type 2 diabetes.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/05/Depression-and-CVD-5.4.2023-scaled-e1683163830556.jpg)
Preventive Cardiology May 4, 2023
Unraveling Depression’s CVD Link May 4, 2023
People with depression have up to 72% higher risks of developing cardiovascular disease, but there’s still many scientific blindspots regarding the links between depression and CVD. Two new studies added visibility to those blindspots, particularly related to prenatal depression and psychotherapy.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Polypill-5.1.2023-scaled-e1682719601953.jpg)
Cardiology Pharmaceuticals May 1, 2023
A Case for Antihypertensive Polypills May 1, 2023
A new JAMA Cardiology study suggests that many hypertension patients could benefit from beginning their treatment with “polypills” featuring a combination of three or four low-dose antihypertensives, rather than starting with one or two BP-lowering agents and escalating if they don’t prove effective.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/CVAUSA-Novocardia-4.27.2023-e1682557668992.jpg)
Cardiology Practices April 27, 2023
Cardiovascular Associates Bolsters VBC Capabilities with NovoCardia Acquisition April 27, 2023
Private equity-backed and value-based care-focused cardiology group acquisitions have become an almost weekly occurrence in 2023, but Cardiovascular Associates of America’s (CVAUSA) acquisition of NovoCardia introduced a new telehealth-led angle to this trend.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Toku-4.24.2023.jpg)
Artificial Intelligence April 24, 2023
Toku Envisions Retail-Based Retinal CVD and Diabetes Screening April 24, 2023
Cardiovascular disease and diabetes screening might be headed to your neighborhood eyeglasses retailer, at least if retinal AI startup Toku Eyes and its heavyweight optical industry backers prove correct.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Cardiology-AI-4.20.2023-scaled-e1681946514436.jpg)
Artificial Intelligence April 20, 2023
Cardiology’s AI Optimization Opportunity April 20, 2023
Cardiology AI's downstream potential, delayed and early AF ablation outcomes, and plenty of other cardiology news.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Precision-Hypertension-4.17.2023-scaled-e1681576617417.jpg)
Cardiology Pharmaceuticals April 17, 2023
The Potential of Personalized Hypertension Medicine April 17, 2023
A new study out of Sweden shows that people with hypertension can respond significantly better to some treatments than others, suggesting that hypertension treatment decisions might become far more personalized in the future.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Statins-4DayWalks.png)
Preventive Cardiology April 13, 2023
Is Moderate Exercise Safe on Statins? April 13, 2023
An interesting new study out of the Netherlands revealed that statins don’t exacerbate muscle-related harms from prolonged moderate-intensity exercise, and statin-associated muscle symptoms (SAMS) shouldn't stand in the way of physical activity.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/HeartFlow-4.10.2023.png)
Cardiac Imaging April 10, 2023
HeartFlow Lands $215M Series F April 10, 2023
Fourteen months after canceling a SPAC deal that would have helped solidify its FFRCT leadership and drive its expansion across the overall CCTA AI segment, HeartFlow landed a $215M Series F round to help make those goals a reality.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/Echo-AI-RCT-4.6.2023.png)
Artificial Intelligence April 6, 2023
Echo AI Improves LVEF Workflow and Variability April 6, 2023
Cedars-Sinai researchers published what might be the strongest evidence yet of AI’s ability to improve echocardiography workflows and accuracy.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/04/AF-Delays-4.3.2023-scaled-e1680481153693.jpg)
Surgeries & Interventions April 3, 2023
Long AF Ablation Delays Drive Adverse Events April 3, 2023
A new study out of Canada exposed the country’s long atrial fibrillation ablation wait times, while showing how widespread AF ablation delays can have significant public health consequences.
![Procyrion Aortix Pump](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/Procyrion-Aortix-3.30.2023-scaled.jpg)
Surgeries & Interventions March 30, 2023
Procyrion Aortix’s CRS Impact March 30, 2023
Data presented at THT 2023 showed that Procyrion's Aortix pump leads to rapid decongestion and improved kidney function in hospitalized patients with cardiorenal syndrome, representing a key milestone for Procyrion and potentially for CRS treatment.
![Ancora Heart Accucinch](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/Ancora-Heart-Accucinch-3.27.2023.png)
Surgeries & Interventions March 27, 2023
Ancora Heart’s AccuCinch TLVR HF Improvements March 27, 2023
New data suggests that Ancora Heart’s investigational AccuCinch Transcatheter Left Ventricular Restoration (TLVR) system improves heart failure patients’ cardiac structure, quality of life, and function.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/CF-Fitness-3.23.2023-e1679535012329.png)
Preventive Cardiology March 23, 2023
Small Cardiorespiratory Fitness Changes, Big Mortality Impact March 23, 2023
A new JACC study highlighted the massive impact cardiorespiratory fitness has on mortality risks, including even small fitness changes.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/Esperion-Daiichi-3.20.2023-scaled-e1679269520459.jpg)
Cardiology Business March 20, 2023
Esperion and Daiichi Sankyo’s Milestone Faceoff March 20, 2023
Esperion and Daiichi Sankyo went from partners to adversaries, after Daiichi revealed that it doesn't plan on paying Esperion the up to $440M in milestone payments associated with its bempedoic acid cholesterol drug.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/LDL-and-Inflamation-Reduction-3.16.2023-scaled-e1678929586956.jpg)
Cardiovascular Disease March 16, 2023
Inflammation’s ASCVD Risks and Potential March 16, 2023
New data reveals that inflammation is a stronger predictor of future cardiovascular events and death than cholesterol among patients who take statins, suggesting that treatment regimens that target both LDL and vascular inflammation are more likely to reduce atherosclerotic risk.
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/CVD-Risk-Factors-3.13.2023-scaled-e1678671038388.jpg)
Population Health March 13, 2023
Young Adult Risks Factors Predict CVD Tsunami March 13, 2023
Among all the ACC presentations that addressed cardiovascular disease prevention, one particularly alarming study underscored how crucial those preventative actions might be if we’re going to avoid a “tsunami of cardiovascular disease over the long-term.”
![](https://insightlinks.storage.googleapis.com/cardiacwire/2023/03/A23027-ACC23-General-SoMe-Graphics_1080x1080-INSTA-POST_Globe-e1678327782745.jpg)
Cardiology March 9, 2023
Cardiac Wire’s Top 8 Takeaways from ACC 2023 March 9, 2023
ACC 2023 is officially a wrap, and it was by far cardiology’s biggest event in three years. In this story we detail Cardiac Wire’s top eight takeaways from ACC 2023.